OR WAIT 15 SECS
Pharmacists are uniquely poised to combat the opioid crisis. Here's what pharmacists (and Congress) can do about it.
Pharmacists at St. Matthews Community Pharmacy in Louisville, KY, have administered more than 1,000 injections of Vivitrol (a long-acting naltrexone) in an effort to combat the opioid epidemic.
Blaiklock showing VivitrolBut the pharmacists took their program a step further. Not only have they received training that allows them to be reimbursed for administering long-acting injectables, they now provide counseling and appointment reminders in order to improve treatment compliance.
But that is just one program targeting the opioid crisis from St. Matthews. The pharmacy began dispensing naloxone in early 2015, and then began administering long-acting naltrexone two years ago.
NCPA provided a statement to the U.S. Senate Committee on Health, Education, Labor, and Pensions in support of the committee’s hearing on the “Federal Response to the Opioid Crisis” and to provide lawmakers with additional ideas to combat the crisis. “In our community, everyone knows someone who has struggled with opioid, opiate, or heroin addiction. Once we discovered an issue affecting so many of our patients it was important to us to find new and innovative ways to play our role in helping to end this devastating crisis. Therefore, we have decided to attack the problem both from a prevention and treatment standpoint through our naloxone and Vivitrol treatment programs,” wrote Emily Blaiklock, PharmD, a pharmacy intern at St. Matthews, in an attachment to the statement.
St. Matthews is just one example of community pharmacies that are combatting the opioid crisis in their communities, NCPA said. The organization also shared with Congress eight recommendations for leveraging independent community pharmacists’ knowledge and proximity to patients to help address the opioid crisis.
Related article: How Should Opioid Addiction Be Treated?
“NCPA is committed to working collaboratively with members of Congress, the Administration, and other stakeholders in adopting viable solutions to prevent drug abuse and diversion,” it said. “We believe there are efforts in the marketplace that are currently making a difference in the battle against opioid abuse and are scalable, such as expansion of consumer access to naloxone.”
NCPA recommendations include: